Baker Hughes reports third-quarter 2026 results
On Oct. 27, 2026, Baker Hughes reported Q3 revenue of $8.025B (+14% YoY), orders of $10.764B (+31%) and adjusted EPS of $0.70 (+2%); GAAP net income was $411M (-33%) and diluted EPS $0.41 (-33%). Operating cash flow was $1.005B and free cash flow $769M. Results included Chart acquisition contributions.
Baker Hughes Company 8-K (2.02, 7.01): reported results of operations
Baker Hughes reported third-quarter 2026 revenue of $8.0 billion, net income of $411 million, adjusted diluted EPS of $0.70, and orders of $10.8 billion, and said it completed its all-cash acquisition of Chart Industries.
CoStar Group, 8-K (1.01, 2.02, 7.01, 9.01): entered into a material agreement
CoStar Group reported third-quarter 2026 revenue of $952 million, up 14% year over year, net income of $74 million and adjusted EBITDA of $229 million, and raised full-year guidance to $820–$840 million adjusted EBITDA, $3.75–$3.77 billion revenue and $1.38–$1.41 adjusted EPS.
HCA Healthcare Raises FY2026 GAAP EPS Guidance from $28.70-$30.50 to $29.60-$30.50 vs $29.46 Est; Raises FY2026 Sales Guidance from $77.000B-$79.500B to $78.250B-$79.500B vs $78.517B Est
HCA Healthcare Raises FY2026 GAAP EPS Guidance from $28.70-$30.50 to $29.60-$30.50 vs $29.46 Est; Raises FY2026 Sales Guidance from $77.000B-$79.500B to $78.250B-$79.500B vs $78.517B Est（摘要待生成）
HCA Healthcare Q3 2026 Earnings Call Transcript
HCA Healthcare (NYSE:HCA) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
HCA Healthcare Beats Wall Street Estimates, But $400 Million Coverage Gap Trips the Stock
HCA Healthcare beat Q3 2026 estimates and raised guidance, but shares slid following a $400 million pretax hit from rising uninsured patient volumes.
Reuters: HCA’s broadly flat 2027 earnings outlook pressures hospital shares
On Oct. 27, CEO Sam Hazen said HCA expects 2027 earnings to be generally consistent with 2026; a full outlook is due in January. HCA expects 2%–3% volume growth, but cited uninsured-patient increases, exchange contraction and lower Medicaid payments. Shares fell more than 5%; Tenet fell 2% and UHS 6%. HCA said Q3 uninsured-patient mix cut pretax income about $400M.
HCA shares fell 3.29% on Q3 results despite beating estimates
Event date: 2026-10-27. HCA closed at $449.96, down $15.30 (3.29%) from $465.26. Q3 adjusted EPS was $7.22 versus estimates of $6.63-$6.74; revenue was $19.849B versus $19.33B estimates. Net income fell 3.9% to $1.579B. HCA said FY26 results should be in the upper half of prior guidance ranges.
Ventas Raises FY2026 FFO Guidance from $3.85-$3.90 to $3.87-$3.90 vs $3.88 Est
Ventas Raises FY2026 FFO Guidance from $3.85-$3.90 to $3.87-$3.90 vs $3.88 Est（摘要待生成）
Ventas reports Q3 2026 results and raises full-year guidance
On October 27, 2026, Ventas reported Q3 results for the quarter ended September 30: attributable net income was $0.13/share, down 7% year over year; Nareit FFO was $1.01/share, up 15%; Normalized FFO was $0.99/share, up 10%. Total NOI rose 18%, same-store cash NOI 11%, and SHOP same-store cash NOI 16%. It closed $1.2B of senior-housing investments in Q3 and $5.2B year to date. 2026 guidance rose t
UHS shares fall as HCA outlook weighs on hospital stocks; Q3 operating detail shows payment pressure
On October 27, UHS shares closed 4.6% below open and fell further in after-hours trading; Fierce Healthcare attributed the reaction partly to HCA Healthcare’s tepid 2027 outlook. UHS acute-care same-facility admissions and patient days each rose 4.9%, but revenue per adjusted admission and per patient day fell 1.7%.
Latham’s Investment Funds Practice And Harvey Are Working Together To Develop An AI-Enabled Platform To Help Deliver Technology-Driven Workstreams For Fund Clients
Latham’s Investment Funds Practice And Harvey Are Working Together To Develop An AI-Enabled Platform To Help Deliver Technology-Driven Workstreams For Fund Clients（摘要待生成）
SEC 8-K filed 2026-10-27 (items 2.02, 7.01, 8.01, 9.01)
FOR IMMEDIATE RELEASE INVESTOR CONTACT: MEDIA CONTACT: Frank Morgan Harlow Sumerford 615-344-2688 615-344-1851 HCA Healthcare reports THIRD quarter 2026 results Nashville, Tenn., October 27, 2026 – HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended September 30, 2026. Key third quarter metrics (all percentage changes compare 3Q 2026 to 3Q 2025 unless otherwise noted): • Revenues increased 3.6 percent to $19.849 billion • Net income attributable to HCA Healthcare, Inc. declined 3.9 percent to $1.579 billion • Diluted earnings per share i
Vertiv Co 8-K (2.01, 7.01, 9.01): completed an acquisition or disposition
Vertiv completed its acquisition of UtilityInnovation Group for approximately $1.45 billion in upfront cash, with up to $1.15 billion in contingent cash consideration tied to EBITDA targets, and expects the deal to boost adjusted EPS in its first year.
JPMorgan upgraded Genmab to Overweight and raised its target
Published Oct. 27; JPMorgan upgraded Genmab from Neutral to Overweight and raised its target to DKK3,500 from DKK2,050, ahead of a November first-line petosemtamab Phase 3 interim head-and-neck readout. Analyst Zain Ebrahim expected at least 40% overall response and raised unadjusted peak-sales forecast to $5B from $2.5B. The article reported shares had risen 68% in six months.
HCA Healthcare Q3 Adj. EPS $7.22 Beats $6.66 Estimate, Sales $19.849B Beat $19.332B Estimate
HCA Healthcare Q3 Adj. EPS $7.22 Beats $6.66 Estimate, Sales $19.849B Beat $19.332B Estimate（摘要待生成）
HCA Healthcare Declares Quarterly Cash Dividend
HCA Healthcare announced a quarterly cash dividend payable on December 29, 2026.
Why Is Intuitive Machines Stock Surging on Tuesday?
Intuitive Machines (NASDAQ: LUNR) stock moves higher Tuesday as small-cap space equities rebound from a month-long selloff. Track key volume and performance metrics.
Ventas Q3 FFO $0.99 Beats $0.98 Estimate, Sales $1.832B Beat $1.757B Estimate
Ventas Q3 FFO $0.99 Beats $0.98 Estimate, Sales $1.832B Beat $1.757B Estimate（摘要待生成）
UBS Maintains Neutral on Mosaic, Lowers Price Target to $19
UBS Maintains Neutral on Mosaic, Lowers Price Target to $19（摘要待生成）
UBS cut Mosaic price target to $19 from $23
Published October 27; the page reports UBS lowered its MOS target from $23 to $19 and maintained Neutral. No rationale or same-day stock/peer reaction was provided in the item.
U.S. technology company orders about 1.1 GW of power and cooling
On Oct. 27, 2026, Baker Hughes announced a major U.S. technology company order for about 1.1 GW of power generation: 34 Frame 5 turbines, nine NovaLT16 turbines, generators and gears. The order also includes Chart dry coolers. Power equipment was booked in Q3 2026; dry coolers in Q4 2026. Customer and contract value were not disclosed.
Thomson Reuters stock rises 4.24% on Oct. 20 and 6.94% on Oct. 22
The page reports TRI rose 4.24% to $112.82 on Oct. 20 and 6.94% to $123.26 on Oct. 22, then fell 0.07% on Oct. 23. On Oct. 27 the shares closed at $116.41, down 4.64%. It gives no company-specific cause or peer comparison.